Prognosis and Treatment Outcomes of Patients with Mixed Adenoneuroendocrine Carcinoma (MANEC) Abstract #1510

Introduction: Mixed adenoneuroendocrine carcinomas (MANEC) are rare tumors, commonly treated in analogy to adenocarcinomas (AC) or neuroendocrine carcinomas (NEC) without systematic data regarding response to therapy.
Aim(s): To analyze the treatment outcomes of MANEC patients.
Materials and methods: Retrospective analysis of all patients with MANEC at our center between 12/2011 and 09/2015.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. med. Leonidas Apostolidis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1919 Prognosis and Treatment Outcomes of Patients with Mixed Adenoneuroendocrine Carcinoma (MANEC) – A Single Cancer Center Experience.
Introduction: Mixed adenoneuroendocrine carcinomas (MANEC) are rare tumors, commonly treated in analogy to adenocarcinomas (AC) or neuroendocrine carcinomas (NEC) without systematic data regarding the optimal treatment strategy.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. med. Leonidas Apostolidis
#2250 Treatment Outcomes of Patients with Mixed Neuroendocrine Non-Neuroendocrine Neoplasms (MiNEN)
Introduction: Mixed neuroendocrine non-neuroendocrine neoplasms (MiNEN) have been newly defined in the WHO 2017 classification. They are rare tumors, commonly treated in analogy to their non-neuroendocrine (nNE) or neuroendocrine (NE) component without systematic data regarding the optimal therapeutic strategy.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis
#2855 Whole Exome Sequencing Reveals the Monoclonal Origin of Gastric Mixed Adenoneuroendocrine Carcinomas
Introduction: Gastric mixed adenoneuroendocrine carcinomas (g-MANECs) are rare neoplasms consisting of adenocarcinoma and neuroendocrine neoplastic components. G-MANECs show more malignant characteristics than gastric adenocarcinomas, while molecular mechanisms underlying the co-existence of the two components remains unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: M.D. Shida Yan
Authors: Yan S, Chen X, Zhang R, Song L, ...
#2941 Mixed Urothelial and Neuroendocrine Carcinoma of the Urinary Bladder: Case Report and Literature Review
Introduction: Neuroendocrine tumors (NETs) comprise
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Mohammed Alaeddine Saidi
Authors: Saidi M A, Ghomari S, ...
#3080 Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)
Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr. med. Leonidas Apostolidis